CDT. Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics. ITASCA, IL, US and HU ...

Biocartis is committed to helping cancer patients worldwide access the right treatment faster. With our proprietary Idylla™ Platform, we deliver in-house molecular biomarker results in only 3 hours, ...

(Reuters) - Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic ...

Researchers evaluated the use of the Idylla™ ctKRAS and ctEGFR Mutation Assays on cytology supernatants from lung cancer patients. The study demonstrated high concordance with next-generation ...

Mechelen, Belgium, 4 April 2019 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of its 2018 ...

Mechelen, Belgium, 29 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will publish its ...

Molecular diagnostics company Biocartis and Royal Philips Electronics announced the signing of an agreement that will result in Biocartis acquiring Philips' technology platform for fully-automated DNA ...

Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive personalized medicine and improve the diagnosis of disease, today announced the ...

Apollo is a compact, scalable system for the detection and quantification of multiple DNA- or RNA-based biomarkers. Biocartis completed a €71 million (almost $95.74 million) Series C equity ...

Funds Will be Used to Commercialize a Fully Automated, Compact Molecular Diagnostics System Designed to Drive the Widespread Adoption of Personalized Medicine and Other Diagnostic Applications ...

Mechelen, Belgium, and London, UK, 1 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the ...